In a combined statement from the AHA, ACC, and ACG, they have recommended expanding use of PPI’s in patients on antiplatelet or NSAID agents at risk for GI bleeding (guidelines). In patients who need an antiplatelet agent, they should be prescribed a PPI if they are at risk for GI bleeding (history of GI bleed or PUD, need for 2 or more antiplatelets, or concomitant anti-coagulation). Additionally, those starting anti-platelet therapy monotherapy with >1 risk factor (age>60, steroids, dyspepsia or GERD ) should also be started on a PPI. Also, in those with a history of PUD, Hyplori testing (and treatment) should be done before starting antiplatelet therapy. All of this is summarized in the following figure (figure)
Share This Post
Categories
Related Posts
While all of us see patients who smoke in their 70s or 80s, due to their limited lifespan from COPD, DM, malignancy, etc., and their expressed wishes to continue tobacco, we keep our admonitions to a minimum. We accept our patient has become learned enough through life to make their own decisions and accept whatever […]
Do you have a stack of journals piling up on your desk, beside your bed or in your email inbox? In 1950, medical knowledge was estimated to double every 50 years, but now the doubling time is every few months. At this rate, it is impossible to keep up with the literature, but a group […]
Fill in the Blanks: Q: “The diagnosis of type 2 MI is associated with a _____ prognosis. ___% of patients will live five years after their diagnosis.” The answer is a) POOR and b) a staggering 40%. I did not know that. However, what I am aware of is the ambiguity around Type 2 MIs and […]
Leave A Comment